X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


Latest Post

June 11, 2019

Particulate Challenges

Particulates in injectable drug products continue to be an area of great interest in the industry. The main reason is the potential clinical effects on patients, which can range from emboli to inflammations to infections. There are a series of clinical risk factors that should be considered in evaluating and mitigating these challenges. These factors are route of administration, patient population, and particulate composition (i.e., number, size, and shape). All are critical inputs to understanding risk and determining corrective and preventative actions.
Fran DeGrazio

Fran DeGrazio

V.P. Technical Customer Service & Scientific Affairs

Previous Posts
Leo Posner of Johnson & Johnson presenting at the PDA Combo Workshop

April 03, 2019

The Challenges of Combination Products

Fran DeGrazio

Fran DeGrazio

VP, Technical Services and Scientific Affairs

Compatibility issues Chart

March 07, 2019

Simplify the Journey™ - Integrated Solutions for Particles

Doug Hostetler

Doug Hostetler

Sr Manager, Integrated Solutions, Lab

Particle Testing

March 01, 2019

Achieving ″Zero″ Defects for Visible Particles in Injectables

Olga Laskina

Olga Laskina

Sr Tech Acct Spec, TCS, NA

Leur Lock Syringes

February 25, 2019

Particles in Intravitreal Injections - Part II

Susan Dounce

Susan Dounce

Principal SME, PFS CZ, TCS

Analytical Laboratory

February 22, 2019

West Analytical Services Introduces New Particle Testing Capabilities

Deirdre Swinden

Deirdre Swinden

Director, Marketing Communications

Load more